In This Article:
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) will be reporting earnings tomorrow before market hours. Here’s what you need to know.
Quest beat analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $2.62 billion, up 14.6% year on year. It was a strong quarter for the company, with a narrow beat of analysts’ sales volume estimates and a decent beat of analysts’ EPS estimates.
Is Quest a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Quest’s revenue to grow 10.7% year on year to $2.62 billion, improving from the 1.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.15 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Quest has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.5% on average.
Looking at Quest’s peers in the healthcare providers & services segment, only UnitedHealth has reported results so far. It missed analysts’ revenue estimates by 1.7%, delivering year-on-year sales growth of 9.8%.
Read our full analysis of UnitedHealth’s earnings results here.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.